Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

التفاصيل البيبلوغرافية
العنوان:	Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine
المؤلفون:	Taft, David, Vora, Tarang, Ren, Chen, Zbyszewski, Patrick S., Morgan, Joseph, Petrone, Michael E., Fruchtman, Steven M., Maniar, Manoj
المصدر:	Blood; November 2018, Vol. 132 Issue: Supplement 1 p4379-4379, 1p
مستخلص:	Taft: Onconova Therapeutics, Inc: Research Funding. Ren:Onconova Therapeutics, Inc: Employment, Equity Ownership. Zbyszewski:Onconova Therapeutics, Inc: Employment, Equity Ownership. Morgan:Onconova Therapeutics, Inc: Consultancy. Petrone:Onconova Terapeutics Inc.: Employment, Equity Ownership. Fruchtman:Onconova Therapeutic Inc: Employment, Equity Ownership. Maniar:Onconova Therapeutics, Inc: Employment, Equity Ownership.
قاعدة البيانات:	Supplemental Index

الوصف
تدمد:	00064971 15280020
DOI:	10.1182/blood-2018-99-118463